Status:
COMPLETED
Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients
Lead Sponsor:
Yuhan Corporation
Conditions:
Ischemic Stroke
Eligibility:
All Genders
60+ years
Brief Summary
This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients
Eligibility Criteria
Inclusion
- Men and women over 60 years old at the time of written consent
- Those admitted to the hospital within 72 hours after acute cerebral infarction and treated with Aspirin 100 mg and Clopidogrel 75 mg
- Written informed consent voluntarily signed
Exclusion
- Those with evidence other brain lesions such as brain tumors
- Those who need oral anticoagulants other than vitamin K antagonists or anticoagulant therapy of warfarin
- Contraindicate to Aspirin or Clopidogrel or allergic to the drug
- Subjects who are at risk of active pathological bleeding such as digestive ulcer and intracranial hemorrhage
- Cancer disease that can shorten life expectancy
- Patient's condition that may interfere with participation in study such as mental illness, mental retardation, dementia, drug abuse, and alcoholism
- Subjects other than the above unsuitable for this clinical study identified by Investigator
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 3 2022
Estimated Enrollment :
1011 Patients enrolled
Trial Details
Trial ID
NCT03823274
Start Date
April 1 2019
End Date
January 3 2022
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungnam National University Hospital
Daejeon, South Korea